Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18490289 | 0.89 | TBXAS1 (0.41) | PTPN2CCNCCDK8HDAC1HDAC3 | |
| SCHEMBL31550045 | 0.87 | PTPN2 (0.43) | OPRD1PTPN2CCNCCDK8CSNK2A2 | |
| SCHEMBL26622018 | 0.85 | PTPN2 (0.47) | PTPN2L3MBTL1KDM4EGAAMAPT | |
| SCHEMBL829006 | 0.84 | CSNK2A2 (0.46) | PTPN2CCNCCDK8CSNK2A2KDR | |
| SCHEMBL21406179 | 0.80 | STING1 (0.49) | KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21452740 | 0.78 | NPC1 (0.38) | PTPN2L3MBTL1GAANPC1RAB9A | |
| SCHEMBL29749445 | 0.78 | SLC9A1 (0.57) | PTPN2CCNCCDK8CSNK2A2KDR | |
| SCHEMBL828976 | 0.78 | SLC9A1 (0.57) | PTPN2CCNCCDK8CSNK2A2KDR | |
| SCHEMBL21341413 | 0.78 | HDAC1 (0.51) | PTPN2CCNCCDK8CSNK2A2KDR | |
| SCHEMBL5550652 | 0.77 | ICAM1 (0.56) | PTPN2CCNCCDK8CSNK2A2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111971277-B | Benzothiophenes and related compounds as STING agonists | 默沙东有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-3774764-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS STING AGONISTS | Merck Sharp&Dohme Corp. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-111971277-A | Benzothiophenes and related compounds as STING agonists | 默沙东公司 | 2020-11-20 | — | — | CN | disclosed |
| US-10793557-B2 | Sting agonist compounds | MERCK SHARP & DOHME CORP. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10793557-B2 | Sting agonist compounds | MERCK SHARP & DOHME CORP. (US) | 2020-10-06 | — | — | US | disclosed |
| WO-2019195124-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195124-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190300513-A1 | STING AGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190300513-A1 | STING AGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-10-03 | — | — | US | disclosed |
| US-9920040-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-20 | — | — | US | disclosed |
| US-9908873-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-06 | — | — | US | disclosed |
| US-9856245-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-02 | — | — | US | disclosed |
| US-20170044146-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044148-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| WO-2017027310-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027309-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027312-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044147-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044148-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | OPRD1 402/4885PTPN2 2029/4885CCNC 1489/4885 |
| US-20190300513-A1 | STING AGONIST COMPOUNDS | STING1, CGAS, IRF3 | OPRD1 1386/4885PTPN2 2556/4885CCNC 3553/4885 |
| US-10793557-B2 | Sting agonist compounds | STING1, CGAS, IRF3 | OPRD1 1386/4885PTPN2 2556/4885CCNC 3553/4885 |
| US-20170044146-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | OPRD1 328/4885PTPN2 1823/4885CCNC 4503/4885 |
| US-20170044147-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR55, GPR65 | OPRD1 378/4885PTPN2 2431/4885CCNC 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.